Systemic delivery of therapeutic viruses

Michael A. Barry, Sean E. Hofherr, Christopher Y. Chen, Julien S. Senac, Matthew L. Hillestad, Elena V. Shashkova

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


The treatment of certain diseases will require the systemic delivery of therapeutic genes or viruses. In most cases, intravascular injection is the best delivery method to achieve the systemic distribution of viruses and to enable these agents to reach distant therapeutic sites. However, viruses administered by intravascular injection encounter overlapping barriers that impede their ability to reach their targets, including interactions with blood cells, blood factors and endothelial cells, loss to hepatocytes and macrophages, and destruction by innate and adaptive immune responses. In this review, recent advances in the understanding of the mechanisms determining virus tropism following systemic administration and the pharmacology of therapeutic viruses are described. Adenoviruses are used as a paradigm of these interactions, and factors affecting their therapeutic efficacy and side effects are discussed, as well as how the barriers that impede their ability to reach their targets translate to other therapeutic viruses.

Original languageEnglish (US)
Pages (from-to)411-420
Number of pages10
JournalCurrent Opinion in Molecular Therapeutics
Issue number4
StatePublished - Aug 2009


  • Biodistribution
  • Blood cell
  • Blood coagulation factor
  • Neutralizing antibody
  • Systemic delivery
  • Therapeutic virus

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)


Dive into the research topics of 'Systemic delivery of therapeutic viruses'. Together they form a unique fingerprint.

Cite this